Published in J Exp Med on February 01, 1987
Rapid effector function in CD8+ memory T cells. J Exp Med (1997) 6.36
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol (1996) 4.45
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest (2008) 4.30
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol (1991) 3.29
Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med (1988) 2.73
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest (1995) 2.66
Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J Exp Med (1995) 2.55
Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med (1991) 2.33
Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes. J Exp Med (1987) 2.28
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol (2001) 2.16
Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol (2010) 2.11
Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol (1998) 2.10
The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol (2002) 2.05
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther (2012) 1.72
The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol (1990) 1.57
Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol (1992) 1.51
Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 1.42
Toward a broadly protective influenza vaccine. J Clin Invest (2008) 1.40
Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J (2010) 1.39
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol (1988) 1.37
Measles virus nucleocapsid protein protects rats from encephalitis. J Virol (1991) 1.33
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology (1991) 1.30
Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol (2013) 1.22
Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J (2009) 1.18
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite): a comparison of T- and B-cell antigen recognition. Immunology (1987) 1.15
Expression of bovine herpesvirus 1 glycoproteins gI and gIII in transfected murine cells. J Virol (1988) 1.14
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One (2009) 1.13
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol (2011) 1.13
Quantitating T cell cross-reactivity for unrelated peptide antigens. J Immunol (2009) 1.11
Evasion of influenza A viruses from innate and adaptive immune responses. Viruses (2012) 1.06
Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest (1989) 1.04
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses (2014) 1.04
MHC class II restriction specificity of cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite). Immunology (1988) 1.03
Characterization of the human CD8⁺ T cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol (2011) 1.02
Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses. J Virol (2006) 1.00
Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T lymphocytes. J Exp Med (1989) 1.00
Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. Respir Res (2007) 0.99
Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol (2008) 0.95
Immune recognition of HLA molecules downmodulates CD8 expression on cytotoxic T lymphocytes. J Exp Med (1991) 0.93
Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One (2013) 0.91
Identification of novel avian influenza virus derived CD8+ T-cell epitopes. PLoS One (2012) 0.89
Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1996) 0.89
Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One (2011) 0.86
Narrowing of human influenza A virus-specific T cell receptor α and β repertoires with increasing age. J Virol (2015) 0.86
The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. Clin Exp Immunol (2007) 0.85
A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) (2014) 0.85
Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol (2009) 0.85
Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype N1. J Virol (1990) 0.83
The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother (2010) 0.81
Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immun Ageing (2011) 0.80
Parainfluenza type 1 virus-infected cells are killed by both CD8+ and CD4+ cytotoxic T cell precursors. Clin Exp Immunol (1993) 0.79
Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med J (2013) 0.79
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front Immunol (2016) 0.79
Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. J Virol (1996) 0.78
Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One (2010) 0.78
Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide. PLoS One (2007) 0.77
Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells. Virol J (2013) 0.76
Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum. Sci Rep (2016) 0.75
Influenza and Memory T Cells: How to Awake the Force. Vaccines (Basel) (2016) 0.75
Chronic spinal cord injury attenuates influenza virus-specific antiviral immunity. J Neuroinflammation (2016) 0.75
Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8(+) T cell epitope. Nat Struct Mol Biol (2017) 0.75
MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol (1979) 15.58
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 8.49
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell (1985) 5.25
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity. Eur J Immunol (1977) 4.05
Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell (1984) 3.97
The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med (1984) 2.81
Influenza virus-specific cytotoxic T cells in man; induction and properties of the cytotoxic cell. Eur J Immunol (1978) 2.39
Declining T-cell immunity to influenza, 1977-82. Lancet (1983) 2.34
Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol (1986) 2.16
Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer. J Exp Med (1984) 2.10
HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes. J Exp Med (1986) 2.09
Virus specificity of human influenza virus-immune cytotoxic T cells. J Immunol (1979) 1.83
Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol (1986) 1.62
Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity. Immunogenetics (1985) 1.20
Inhibition of human T lymphocyte function with monoclonal antibodies. Br Med Bull (1984) 1.17
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
The time relations of the photo-electric changes in the eyeball of the frog. J Physiol (1903) 31.79
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Studies in the biochemistry of micro-organisms: The metabolic products of the Penicillium brevi-compactum series. Biochem J (1932) 11.42
Confidential inquiry into quality of care before admission to intensive care. BMJ (1998) 11.32
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Studies in the biochemistry of micro-organisms: The metabolic products of Penicillium Charlesii G. Smith. Biochem J (1934) 10.22
The delay of the electrical response of nerve to a second stimulus. J Physiol (1910) 9.35
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
Studies in the biochemistry of micro-organisms: The metabolic products of Aspergillus terreus Thom. A new mould metabolic product-terrein. Biochem J (1935) 7.74
Studies in the biochemistry of micro-organisms: The metabolic products of Aspergillus terreus Thom. Part II. Two new chlorine-containing mould metabolic products, geodin and erdin. Biochem J (1936) 6.60
Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol (1987) 6.13
In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol (1985) 5.77
Hours, volume, and type of work of preregistration house officers. BMJ (1990) 5.68
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci U S A (1982) 5.25
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature (1983) 5.25
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc Natl Acad Sci U S A (1989) 5.23
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Methylated nucleotides block 5'-terminus of vaccinia virus messenger RNA. Proc Natl Acad Sci U S A (1975) 5.16
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol (1988) 4.92
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature (1987) 4.66
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell (1981) 4.42
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations. J Virol (1983) 3.95
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94
Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 3.87
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol (1991) 3.79
Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature (1969) 3.74
Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques (1997) 3.74
Studies in the biochemistry of micro-organisms: The metabolic products of Byssochlamys fulva Olliver and Smith. Biochem J (1933) 3.74
Structure of vaccinia virus early promoters. J Mol Biol (1989) 3.73
Methylation of newly synthesized viral messenger RNA by an enzyme in vaccinia virus. Proc Natl Acad Sci U S A (1974) 3.68
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc Natl Acad Sci U S A (1985) 3.61
Alternative equilibria in shallow lakes. Trends Ecol Evol (1993) 3.55
Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science (1985) 3.54
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol (1992) 3.53
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology (1987) 3.53
Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. Proc Natl Acad Sci U S A (1970) 3.50
Methylated nucleotides block 5' terminus of HeLa cell messenger RNA. Cell (1975) 3.46
Structure of vaccinia virus late promoters. J Mol Biol (1989) 3.42
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
Inhibition of HeLa cell protein synthesis by the vaccinia virion. J Virol (1968) 3.28
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature (1984) 3.21
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. J Virol (1990) 3.18
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 3.17
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Cell-free translation of early and late mRNAs selected by hybridization to cloned DNA fragments derived from the left 14 million to 72 million daltons of the vaccinia virus genome. Virology (1981) 3.10
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. Proc Natl Acad Sci U S A (1986) 3.07
Cardiovascular and catecholamine responses to laryngoscopy with and without tracheal intubation. Br J Anaesth (1987) 3.05
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (1994) 3.05
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry (1998) 3.02
Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition. J Virol (1982) 3.01
Interruption by Rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes. J Virol (1970) 3.00
Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. EMBO J (1986) 3.00
Hydroxylapatite chromatography of protein-sodium dodecyl sulfate complexes. A new method for the separation of polypeptide subunits. J Biol Chem (1972) 2.97
Transient dominant selection of recombinant vaccinia viruses. J Virol (1990) 2.97
In vitro translation of immediate early, early, and late classes of RNA from vaccinia virus-infected cells. Virology (1979) 2.97
Sequential protein synthesis following vaccinia virus infection. J Virol (1968) 2.89
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 2.85
Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A (1987) 2.84
Regulation of expression and nucleotide sequence of a late vaccinia virus gene. J Virol (1984) 2.84
Purification and characterization of a transcription termination factor from vaccinia virions. J Biol Chem (1987) 2.83
A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology (1995) 2.82
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology (1993) 2.81
Genome-wide analysis of vaccinia virus protein-protein interactions. Proc Natl Acad Sci U S A (2000) 2.81
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J Virol (1996) 2.77
Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell (1982) 2.76
Modification of RNA by mRNA guanylyltransferase and mRNA (guanine-7-)methyltransferase from vaccinia virions. J Biol Chem (1975) 2.76
Vaccinia virus expression vectors. Annu Rev Immunol (1987) 2.75